TM
KYMR icon

Torren Management’s Kymera Therapeutics KYMR Stock Holding History

Torren Management’s Portfolio KYMR Stock Details KYMR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.75K Hold
24
– – ﹤0.01% 483
2026
Q1 		$2K Hold
24
– – ﹤0.01% 552
2025
Q4 		$1.87K Buy
+24
New +$1.62K ﹤0.01% 1081

Other funds holding KYMR

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
MC
Merck & Co Kenilworth, New Jersey $526M AUM 175.27% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return
TD Asset Management
TD Asset Management Toronto, Ontario, Canada $115B AUM 41.58% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $315B AUM 27.84% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
TCM
TimesSquare Capital Management New York $6.8B AUM 45.85% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return

Torren Management's KYMR Position: Q2 2026 in Review

Torren Management held its Kymera Therapeutics (KYMR) position steady in Q2 2026 at 24 shares worth $2.75K. The position accounts for ﹤0.01% of the portfolio, ranked #483.

Torren Management first reported a position in KYMR in Q4 2025 and has held it in 3 quarters since. 93 funds tracked by Wall St. Rank hold KYMR as of Q2 2026.

  • Torren Management held 24 shares of Kymera Therapeutics worth $2.75K as of Q2 2026.
  • Torren Management left its Kymera Therapeutics share count unchanged in Q2 2026.
  • Kymera Therapeutics made up ﹤0.01% of Torren Management's portfolio in Q2 2026, its #483 holding.
  • Torren Management first reported a position in Kymera Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • 93 funds tracked by Wall St. Rank held Kymera Therapeutics as of Q2 2026.

Based on Torren Management's 13F filing for Q2 2026, filed 10 Jul 2026.